[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fourth Affiliated Hospital of Guangxi Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100495741","phase-3-concurrent-chemoradiotherapy-combined-with-adjuvant-chemotherapy-treated-advanced-cervical-cancer-100495741",false,"NCT05735145","Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer","A Prospective Randomized Controlled Trial for Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy in the Treatment of Advanced Cervical Cancer at 2018 FIGO Staging","Inclusion Criteria:\n\n* Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma\n* FIGO stage IB3, IIA2, IIB-IVA patients in 2018\n* Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment\n* Aged 18-75 years\n* PS score 0-1\n* Serum hemoglobin \\>=100\\*10\\^9\u002FL, blood platelet \\>= 100000\u002FμL, absolute count of neutrophils\\>=1500\u002FμL; 7.Serum creatinine \\\u003C=1.5 UNL or creatinine clearance \\>= 60 ml\u002Fmin; 8.Serum bilirubin \\\u003C=1.5 UNL, AST (SGOT) and ALT (SGPT)\\\u003C= 1.5 UNL\n* Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival \\> 6 months.\n\nExclusion Criteria:\n\n* Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after treatment\n* Patients who have received neoadjuvant chemotherapy and surgery\n* Patients with cognitive impairment\n* Patients with any distant metastases\n* Patients with any other malignancy within 5 years\n* Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy, etc.); 5.Pregnant or lactating women, or fertile women who do not use contraception\n* Severe bone marrow dysfunction\n* Patients with bleeding tendency\n* Drug abusers or alcohol addicts\n* Those who are known to have a third or fourth degree allergic reaction to any treatment in the study","FEMALE","18 Years","75 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.",[27,28,29],"Uterine Cervical Neoplasms","Chemoradiotherapy","Adjuvant Chemotherapy","RECRUITING","2023-02-16",{"date":33,"type":34},"2023-02-21","ACTUAL",{"date":36,"type":34},"2022-07-01",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Fourth Affiliated Hospital of Guangxi Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100494408","concurrent-and-adjuvant-nimotuzumab-combined-with-induction-chemotherapy-plus-chemoradiation-in-nasopharyngeal-carcinoma-100494408","NCT05717790","Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma","Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation and Adjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Age: 18 to 70.\n2. Pathological type: non-keratinizing carcinoma (World Health Organization criteria).\n3. Diagnosed with LANPC (stage III-IV, except for patients with T3N0)) according to the 8th edition clinical staging system of the American Joint Committee on Cancer \\[AJCC\\]\u002FUnion for International Cancer Control \\[UICC\\].\n4. ECOG performance score: 0 to 1.\n5. Primary lesions can measurable.\n6. Adequate marrow function: neutrocyte count≥1.5×10e9\u002FL, hemoglobin ≥90g\u002FL and platelet count ≥100×10e9\u002FL.\n7. Alanine Aminotransferase (ALT)\u002FAspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and creatinine clearance rate ≥ 50 ml\u002Fmin (Cockcroft-Gault formula).\n8. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.\n\nExclusion Criteria:\n\n1. Primary lesions or lymph node have been operated (except of operation for biopsy).\n2. Previous Received other anti EGFR monoclonal antibody treatment;Previous chemotherapy or immunization therapy.\n3. Other malignant tumor.\n4. Participation in other interventional clinical trials within 1 month.\n5. History of Serious lung or heart disease.\n6. Pregnant or breast-feeding women and women who refused to take contraceptive method.\n7. Drug abuse or alcohol addiction.\n8. History of serious allergic or allergy.\n9. Refused or can't signed informed consent form.\n10. Other patients who are considered ineligible for the study by the investigator.","ALL","70 Years",{"count":53,"type":21},288,[55],"NA","Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This is a multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of nimotuzumab combined with induction chemotherapy plus chemoradiation and adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.",[58],"Nasopharyngeal Carcinoma by AJCC V8 Stage",[60,61,62,63,64],"Nimotuzumab","Nasopharyngeal Carcinoma","Induction Chemotherapy","Chemoradiation","Adjuvant Therapy","2023-01-29",{"date":67,"type":34},"2023-02-08",{"date":69,"type":34},"2022-12-01",{"date":71,"type":21},"2027-11-30",{"name":40,"class":41},9,""]